<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article84</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ISAR-REACT_5" style="display:block; margin-bottom:10px;">ISAR-REACT 5 Original</a></li>
<h2><strong>ISAR-REACT 5</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ticagrelor versus Prasugrel in Acute Coronary Syndromes".The New England Journal of Medicine. 2019.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with acute coronary syndromes for whom invasive evaluation is planned, how does ticagrelor compare with prasugrel in preventing death, myocardial infarction, or stroke?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with acute coronary syndromes with or without ST-segment elevation, prasugrel was associated with a significantly lower incidence of death, myocardial infarction, or stroke compared to ticagrelor at 1 year, without a significant difference in the incidence of major bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the time of the trial, both prasugrel and ticagrelor were recommended (class I) for use in patients with acute coronary syndromes with or without ST-segment elevation.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, open-label, phase 4 trial comparing ticagrelor and prasugrel.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
4,018 patients hospitalized with acute coronary syndromes (STEMI, NSTEMI, or unstable angina) with planned invasive evaluation.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Ticagrelor: Loading dose of 180 mg, maintenance dose of 90 mg twice daily.<br/>
Prasugrel: Loading dose of 60 mg, maintenance dose of 10 mg daily; a reduced maintenance dose of 5 mg daily was recommended for patients aged 75+ or weight less than 60 kg. Prasugrel loading was administered after coronary anatomy was known in patients with acute coronary syndromes without ST-segment elevation.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Composite of death from any cause, myocardial infarction, or stroke at 1 year (ticagrelor 9.3% vs. prasugrel 6.9%; hazard ratio 1.36, 95% CI 1.09 to 1.70; P=0.006).<br/>
Safety End Point: Major bleeding (BARC type 3 through 5) (ticagrelor 5.4% vs. prasugrel 4.8%; hazard ratio 1.12, 95% CI 0.83 to 1.51; P=0.46).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open-label design may introduce bias.<br/>
- Most follow-up conducted by telephone, not face-to-face.<br/>
- High incidence of switching to clopidogrel after discharge in a previous head-to-head comparison trial.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by the German Center for Cardiovascular Research and Deutsches Herzzentrum MÃ¼nchen.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
